Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799143 | 1.00 | ENPP2 (0.52) | ENPP2SIGMAR1ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL7033170 | 1.00 | ENPP2 (0.52) | ENPP2SIGMAR1ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL7382258 | 0.93 | ALDH1A1 (0.46) | ENPP2SIGMAR1ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL5123960 | 0.93 | ALDH1A1 (0.52) | ENPP2SIGMAR1ALDH1A1TSHRCCR5 | |
| SCHEMBL27652104 | 0.93 | ALDH1A1 (0.52) | ENPP2SIGMAR1ALDH1A1TSHRCCR5 | |
| SCHEMBL5122891 | 0.93 | ALDH1A1 (0.52) | ENPP2SIGMAR1ALDH1A1TSHRCCR5 | |
| SCHEMBL7275332 | 0.91 | ENPP2 (0.49) | ENPP2SIGMAR1ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL7275912 | 0.86 | ENPP2 (0.42) | ENPP2SIGMAR1ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL15649454 | 0.86 | ENPP2 (0.44) | ENPP2SIGMAR1ALDH1A1TSHRTRPM8 | |
| SCHEMBL15648931 | 0.86 | ENPP2 (0.47) | ENPP2SIGMAR1ALDH1A1TSHRTRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1425009-A4 | PEPTIDE ARGINALS AND METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION | IVAX INST FOR DRUG RES LTD (HU) | 2006-10-25 | — | — | EP | disclosed |
| US-20050070480-A1 | Peptide arginals and methods for treating disseminated intravascular coagulation | IVAX DRUG RESEARCH INSTITUTE LTD. (HU) | 2005-03-31 | — | — | US | disclosed |
| EP-1425009-A2 | PEPTIDE ARGINALS AND METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION | Ivax Institute for Drug Research, Ltd. (HU) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003016273-A2 | PEPTIDE ARGINALS AND METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION | IVAX CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070480-A1 | Peptide arginals and methods for treating disseminated intravascular coagulation | ARGLU1, PLAT, SERPINC1 | ENPP2 823/4885SIGMAR1 4767/4885ALDH1A1 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.